Lv3
218 积分 2024-03-04 加入
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
8天前
已完结
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
8天前
已完结
JAK inhibitors, cardiovascular and thromboembolic events: what we know and what we would like to know
2个月前
已完结
Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS)
2个月前
已完结
Editorial: Moving towards prognostic endoscopic scoring in IBD
2个月前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
3个月前
已完结
Efficacy and safety of different oral prednisone tapering courses in adult anti‐NMDAR encephalitis: A multicenter prospective cohort study
3个月前
已完结
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
3个月前
已完结
Alternative Complement Pathway, Iptacopan, and IgA Nephropathy
5个月前
已完结
Contemporary advances in anti-NMDAR antibody (Ab)-mediated encephalitis
5个月前
已完结
皖公网安备34019202002308
